Abstract

Statistics Core The primary goals of the Statistics Core of the SWOG SDMC are to lead the design, development, and monitoring of rigorous clinical trials and translational medicine studies by using stringent, well-tested processes.
Some specific aims of the Statistics Core faculty and staff are to (a) develop and rapidly implement scientifically sound and efficient clinical trials and collaborate on abstracts and manuscripts to ensure timely dissemination of results; (b) actively monitor ongoing trials using standardized processes and software; (c) conduct and collaborate on statistical methods research, including clinical trial design and the analysis of translational medicine studies; and (d) lead secondary analyses and cross-study research using the SWOG database. The SWOG SDMC Statistics Core approach is to use designs that lead to convincing conclusions, whether for Phase II, Phase III, or translational medicine objectives that guide new cancer treatment and science. As immunotherapy and targeted agents present challenges with respect to statistical evaluation, the Statistics Core faculty develop and evaluate the statistical properties of innovative and efficient designs to advance these new therapies.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180819-08
Application #
10107782
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2014-04-17
Project End
2025-02-28
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
8
Fiscal Year
2021
Total Cost
Indirect Cost

  Institution

Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109

  Publications

Herbst, Roy S; Redman, Mary W; Kim, Edward S et al. (2018) Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol 19:101-114
Othus, Megan; Sekeres, Mikkael A; Nand, Sucha et al. (2018) Relative survival following response to 7?+?3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia :
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Statler, Abby; Othus, Megan; Erba, Harry P et al. (2018) Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood 131:2782-2788
Rimsza, Lisa M; Li, Hongli; Braziel, Rita M et al. (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151-e153
Dai, James Y; Liang, C Jason; LeBlanc, Michael et al. (2018) Case-only approach to identifying markers predicting treatment effects on the relative risk scale. Biometrics 74:753-763
Sharma, P; Barlow, W E; Godwin, A K et al. (2018) Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol 29:654-660
Zhan, Xiang; Wu, Michael C (2018) Reader Reaction: A note on testing and estimation in marker-set association study using semiparametric quantile regression kernel machine. Biometrics 74:764-766
Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146
Halpern, Anna B; Othus, Megan; Huebner, Emily M et al. (2018) Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia :

Showing the most recent 10 out of 156 publications